Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, announces a definitive agreement for Lilly to acquire Adverum Biotechnologies, Inc. (“Adverum”), including its lead product candidate, Ixo-vec. Adverum is developing a pipeline of intravitreal single-administration gene therapies with the aspiration of developing functional cures to restore vision and prevent blindness. Its lead product candidate, Ixo-vec, is an intravitreal gene therapy being developed for the treatment of wet age-related macular degeneration (wAMD).
Read the full article: Lilly to Acquire Adverum Biotechnologies //
Source: https://www.prnewswire.com/news-releases/lilly-to-acquire-adverum-biotechnologies-302593482.html